Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | NAAA | Q02083 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29708225 | 1.00 | HDAC3 (0.74) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| SCHEMBL2128698 | 0.95 | HDAC3 (0.68) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| SCHEMBL5694314 | 0.94 | NAAA (0.68) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| SCHEMBL11083072 | 0.94 | NAAA (0.68) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| SCHEMBL9763677 | 0.94 | NAAA (0.68) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| SCHEMBL25330125 | 0.94 | NAAA (0.68) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| SCHEMBL2868723 | 0.94 | NAAA (0.68) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| SCHEMBL2356495 | 0.94 | NAAA (0.68) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| SCHEMBL11248504 | 0.94 | NAAA (0.68) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| Bromide SCHEMBL9028287 | 0.93 | NAAA (0.67) | HDAC3HDAC1HDAC2RAB9AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481383-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LTD (IN) | 2023-06-14 | — | — | EP | disclosed |
| CN-108026157-B | Novel insulin derivative and medical use thereof | 诺和诺德股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-106459171-B | A22K, desB27, B29R, desB30, human insulin analogs acylated at the position of lysine 22 | 诺和诺德股份有限公司 | 2020-12-15 | — | — | CN | disclosed |
| US-20200087338-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS INC (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2018139876-A1 | NOVEL [1,2,4]TRIAZOLO[4, 3-A]QUINOXALINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BET PROTEIN-RELATED DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | 동화약품주식회사 | 2018-08-02 | — | — | WO | disclosed |
| EP-3169666-B1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2018-06-06 | — | — | EP | disclosed |
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-27 | — | — | US | disclosed |
| WO-2017120355-A1 | DIHYDROQUINOLINES AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2017-07-13 | — | — | WO | disclosed |
| WO-2016044585-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2014121036-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC (US) | 2014-08-07 | — | — | WO | disclosed |
| EP-1354602-A1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | Sankyo Company, Limited (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| US-6432993-B1 | BENZIMIDAZOLE OR IMIDAZO(4,5-B)PYRIDINE DERIVATES; IMMUNOMODULATORS; ALDOSE REDUCTASE AND LIPOXYGENASE INHIBITORS; DIABETES; PREVENTS LIPID PEROXIDATION; ANTILIPEMIC, HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-08-13 | — | — | US | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-1022272-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-4243666-A | HYPOTENSIVE AGENTS | PFIZER INC. (US) | 1981-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087338-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | TYMP, PNP, DUT | HDAC3 2571/4885HDAC1 2609/4885HDAC2 3314/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | HDAC3 346/4885HDAC1 326/4885HDAC2 701/4885 |
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | HDAC3 201/4885HDAC1 90/4885HDAC2 199/4885 |
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRM1, OPRD1 | HDAC3 1139/4885HDAC1 461/4885HDAC2 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.